At the news
? NEUTRALIMPACT 5/10 PRESS-RELEASE filed Mar 2, 2026 at 07:00 ET
Apogee Therapeutics reported full-year 2025 financial results with increased R&D and G&A spending driving a wider net loss, while maintaining a strong cash position of $902.9 million that funds operations into 2H 2028. The company highlighted upcoming clinical milestones for its lead asset zumilokibart in atopic dermatitis, asthma, and EoE, including a head-to-head trial against Dupixent with interim data expected in 2H 2026.
- Cash, cash equivalents, and marketable securities totaled $902.9 million as of December 31, 2025, up from $731.1 million in 2024.
- R&D expenses increased to $214.7 million in 2025 from $167.9 million in 2024.
- G&A expenses rose to $70.9 million in 2025 from $49.0 million in 2024.
- Net loss widened to $255.8 million in 2025 from $182.1 million in 2024.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access